Utilizzo Del Saccharomyces Boulardii Nella Prevenzione Del Danno Intestinale Da Farmaci Anti-infiammatori Non Steroidei
Year: 2026
Type: dissertation
Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat pain and inflammatory conditions, but their use is often associated with adverse digestive effects, including damage to the intestinal mucosa, increased epithelial permeability, alterations in the microbiota, and activation of innate immunity, resulting in inflammation and local injury. The aim of this study was to evaluate the protective effect of the probiotic Saccharomyces boulardii CNCM I-745 (S. boulardii) on the distal small intestine in an animal model of NSAID-induced enteropathy. The study was conducted on 40-week-old male albino rats treated with diclofenac (4 mg/kg twice daily for 14 days) to induce intestinal damage. The probiotic was administered orally twice daily (3 g/kg) according to two protocols: a preventive (14 days before starting diclofenac treatment) and a curative (concurrent with the start of NSAID administration). Treatment with diclofenac resulted in the development of intestinal damage associated with increased levels of myeloperoxidase (MPO, an index of mucosal infiltration by polymorphonuclear cells), malondialdehyde (MDA, an index of oxidative stress), TNF and IL-1β (pro-inflammatory cytokines), activation of the TLR-2, TLR-4, MyD88, and NF-κB p65 pathways, and increased fecal calprotectin and fecal butyrate. Diclofenac also reduced hemoglobin, occludin, and the butyrate transporter MCT1. Finally, the NSAID contributed to alterations in the composition of the intestinal microbiota (in the ileum and feces). Treatment with S. boulardii, in both the preventive and curative protocols, reversed most of these changes. Only preventive administration of the probiotic counteracted the NSAID-induced reduction in MCT1 expression and the increase in fecal butyrate levels. No significant changes in occludin expression were observed after treatment with the probiotic. Treatment with S. boulardii prevents diclofenac-induced enteropathy through anti-inflammatory and antioxidant effects. These effects are likely related to an increase in the tissue bioavailability of butyrate, resulting in improved butyrate absorption by the intestinal mucosa.
Author: SANZONE, ANNA
Language: Italian
Subfield: Food Science
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7208232603
